ReviewAntibiotics (Basel, Switzerland)2022
Antibiotic Discovery and Resistance: The Chase and the Race.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploring the Antibacterial Properties of Acmella Species: A Systematic Literature Review.Drug design, development and therapy · 2026Pooled it
- Untargeted Metabolomics and Bioactivity Screening of Mycelial Culture Extracts from Marasmioid Fungi.Current microbiology · 2026Article
- Strain-level molecular and infection traits are associated with differences in phage efficacy against Pseudomonas aeruginosa.Scientific reports · 2026Article
- Fermented Navy Bean-Derived Agents Restore Antibiotic Susceptibility inJournal of microbiology and biotechnology · 2026Article
- EZ-SPOTs: a simple, low-cost, high-throughput liquid handling platform applied to antimicrobial susceptibility testing of clinical isolates.Lab on a chip · 2026Article
- Efficacy of Antimicrobial Envelopes in Preventing Cardiac Implantable Electronic Device Infection: Systematic Review and Meta-Analysis.Korean circulation journal · 2026Article
- Ultra-High-Throughput Discovery of Multifunctional Polyphenolic Coatings on Droplet Microarrays.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Therapeutic significance of surface-exposed virulence factors in Acinetobacter baumannii pathogenicity.Molecular biology reports · 2026Review
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Klebsiella pneumoniae in humans, animals and the environment in Northwest Amhara, Ethiopia.Scientific reports · 2026Article
- Enhancing the Antimicrobial Efficacy of CTS Through Complexation and Nanoengineering with Zn: Emerging Trends (2018-2025).Applied biochemistry and biotechnology · 2026Review
- Design, Synthesis, In Vitro, and In Silico Assessment of Fluoroquinolone-Sulfonamide Hybrids as Promising Antibacterial Agents.Chemistry & biodiversity · 2026Article
- In Silico Druggability Assessment ofAntibiotics (Basel, Switzerland) · 2026Article
- Amelioration of gentamicin-induced acute kidney injury by trifluoperazine: in vivo mechanistic insights.Scientific reports · 2026Article
- A nutrient bottleneck controls antibiotic efficacy in structured bacterial populations.Nature communications · 2026Article
- Article
- Containment of antimicrobial resistance for strengthening global public health security: Biorisk management perspectives.Biosafety and health · 2026Review
- Amikacin-eravacycline combination mediates the synergistic elimination of carbapenem-resistant pathogens via in vitro and in vivo metabolic reprogramming.PLoS pathogens · 2026Article
- Self-carrier nanodrugs with dual antibacterial agents to overcome tobramycin resistance in multidrug-resistantBioactive materials · 2026Article
- A One Health Perspective on the Plasmid Backbone Preference and Evolutionary Adaptation ofInfection and drug resistance · 2026Article
- Advances in deep learning for antimicrobial research.Frontiers in microbiology · 2026Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The history of antimicrobial resistance (AMR) evolution and the diversity of the environmental resistome indicate that AMR is an ancient natural phenomenon. Acquired resistance is a public health concern influenced by the anthropogenic use of antibiotics, leading to the selection of resistant genes. Data show that AMR is spreading globally at different rates, outpacing all efforts to mitigate this crisis. The search for new antibiotic classes is one of the key strategies in the fight against AMR. Since the 1980s, newly marketed antibiotics were either modifications or improvements of known molecules. The World Health Organization (WHO) describes the current pipeline as bleak, and warns about the scarcity of new leads. A quantitative and qualitative analysis of the pre-clinical and clinical pipeline indicates that few antibiotics may reach the market in a few years, predominantly not those that fit the innovative requirements to tackle the challenging spread of AMR. Diversity and innovation are the mainstays to cope with the rapid evolution of AMR. The discovery and development of antibiotics must address resistance to old and novel antibiotics. Here, we review the history and challenges of antibiotics discovery and describe different innovative new leads mechanisms expected to replenish the pipeline, while maintaining a promising possibility to shift the chase and the race between the spread of AMR, preserving antibiotic effectiveness, and meeting innovative leads requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.